$14.01
-0.64%SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
SIBN โข NASDAQ
| SI-BONE, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||
200.9M | 167.2M | 138.9M | 106.4M | 90.2M | 73.4M | 67.3M | 55.4M | 48M | 42.1M | 41.2M | 40.1M | 49M | 37M | |
GROSS PROFIT | ||||||||||||||
(41M) | (35.1M) | (29.5M) | (15.7M) | (10.4M) | (8.9M) | (6.8M) | (4.8M) | (5.1M) | (5.2M) | (5.4M) | (6.5M) | (4.3M) | (3M) | |
159.9M | 132.1M | 109.4M | 90.7M | 79.7M | 64.5M | 60.5M | 50.5M | 42.9M | 36.9M | 35.8M | 33.6M | 44.7M | 34M | |
OPERATING INCOME | ||||||||||||||
(182.2M) | (167.4M) | (156.4M) | (150.3M) | (131.4M) | (103.1M) | (96.5M) | (62.5M) | (60.2M) | (54.5M) | (62.2M) | (59.8M) | (49.9M) | (44.7M) | |
(164.8M) | (150.8M) | (141.3M) | (136.7M) | (119M) | (93.6M) | (89.2M) | (57.1M) | (54.7M) | (48.1M) | (53.6M) | (50.7M) | (41.6M) | (40.9M) | |
(17.4M) | (16.6M) | (15M) | (13.6M) | (12.4M) | (9.5M) | (7.3M) | (5.4M) | (5.5M) | (6.4M) | (8.6M) | (9.2M) | (8.4M) | (3.8M) | |
-22.3M | -35.2M | -46.9M | -59.6M | -51.7M | -38.6M | -36M | -12M | -17.4M | -17.6M | -26.4M | -26.3M | -5.3M | -10.7M | |
PRE-TAX INCOME | ||||||||||||||
(5.3M) | (3.4M) | (3.5M) | (2.8M) | (5.4M) | (6.1M) | (4.9M) | (5.1M) | (6.2M) | (3.3M) | (0.0) | (0.0) | (0.0) | (0.0) | |
790K | 4.4M | 3.5M | -1.5M | -5.2M | -5M | -2.4M | -4.3M | -6M | -3.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (340K) | (213K) | (0.0) | (0.0) | (0.0) | (0.0) | |
3.4M | 4.3M | 3.6M | -1.6M | -4.9M | -5.1M | -2.4M | -5.5M | -5.7M | -3M | -1.7M | -1.5M | -847K | -184K | |
-18.9M | -30.9M | -43.3M | -61.3M | -56.6M | -43.7M | -38.4M | -17.5M | -23M | -20.6M | -28.2M | -27.8M | -6.1M | -10.9M | |
NET INCOME | ||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2K) | (10K) | (0.0) | |
-18.9M | -30.9M | -43.3M | -61.3M | -56.6M | -43.7M | -38.4M | -17.5M | -23M | -20.6M | -28.2M | -27.8M | -6.2M | -10.9M |
SIBN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 05, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 04, 2025 | July 31, 2025 | 2025 |
Continue your SIBN research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.